HIGHLIGHTS
SUMMARY
Studies have shown encouraging results regarding the safety of the first two doses of the vaccine with respect to maternal, obstetric, and neonatal outcomes, along with encouraging effectiveness including the ability to generate a sufficient humoral immune_response among pregnant women, resulting in a transfer of SARS-CoV-2 IgG to their fetuses. Recent studies have shown that, similar to the first and second doses of the BNT162b2 vaccine, the third dose is also safe in pregnancy and effective in generating a significant humoral immune_response of SARS-CoV-2 IgG in pregnant women and their . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.